Shifting the Curve
October 8, 2012
From: The Canadian Environmental Health Atlas
- risk factor
- lead exposure
- tobacco exposure
- synergistic effect
- public health
video supplement to:
Attention-Deficit/Hyperactivity Disorder: A Preventable Epidemic?
Arch Pediatr Adolesc Med. 2012;166(12):1182-1184.
Virgin’s Richard Branson Bares His Business ‘Secrets’
October 10, 2012
Richard Branson is not your average entrepreneur. He dropped out of school at 15 and, despite suffering from dyslexia and attention deficit disorder, went on to found Virgin Group, a business empire that includes airlines, cellphone companies, banks, hotels, health clubs and even a space travel business.
In his new book, Like a Virgin: Secrets They Won’t Teach You at Business School, Branson reflects on his dyslexia as well as some frequently asked questions about his success.
Animal model of methylphenidate’s long-term memory-enhancing effects
Learn. Mem. January 16, 2014 21: 82-89
Cognitive and emotional behavioural changes associated with methylphenidate treatment: a review of preclinical studies
Int J Neuropsychopharmacol February 1, 2012 15: 41-53
Executive Impairment Determines ADHD Medication Response: Implications for Academic Achievement
J Learn Disabil March 1, 2011 44: 196-212
Living with ADHD in the age of information and social media
train of thought
5:14 AADD: Acquired Attention Deficit Disorder
ADHD As A Difference In Cognition, Not A Disorder
ADHD sucks, but not really
Salif Mahamane | TEDxUSU
Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
Lancet. 2013 Apr 20;381(9875):1371-9.
Cross-Disorder Group of the Psychiatric Genomics Consortium.
Erratum in: Lancet. 2013 Apr 20;381(9875):1360.
Findings from family and twin studies suggest that genetic contributions to psychiatric disorders do not in all cases map to present diagnostic categories.
We aimed to identify specific variants underlying genetic effects shared between the five disorders in the Psychiatric Genomics Consortium: autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia.
We analyzed genome-wide single-nucleotide polymorphism (SNP) data for the five disorders
SNPs at four loci surpassed the cutoff for genome-wide significance (p<5×10(-8)) in the primary analysis: regions on chromosomes 3p21 and 10q24, and SNPs within two L-type voltage-gated calcium channel subunits, CACNA1C and CACNB2.
Model selection analysis supported effects of these loci for several disorders.
Loci previously associated with bipolar disorder or schizophrenia had variable diagnostic specificity.
Pathway analysis supported a role for calcium channel signalling genes for all five disorders.
Our findings show that specific SNPs are associated with a range of psychiatric disorders of childhood onset or adult onset. In particular, variation in calcium-channel activity genes seems to have pleiotropic effects on psychopathology.
These results provide evidence relevant to the goal of moving beyond descriptive syndromes in psychiatry, and towards a nosology informed by disease cause.
Genes and the Human Condition (From Behavior to Biotechnology)
For Kids With ADHD, Some Foods May Complement Treatment
by Allison Aubrey
January 09, 2012
“Elimination diets may help in a very small percentage of patients,” whereas stimulant medications are generally very effective, writes J. Gordon Millichap, a neurologist at Children’s Memorial Hospital in Chicago who authored the paper.
Trigeminal Nerve Stimulation an Option for ADHD?
May 20, 2013
Currently, the system has no approvals in the United States from the US Food and Drug Administration (FDA).
Leon Ekchian, president and CEO of NeuroSigma, Inc, said the company plans first to apply for the epilepsy indication in the United States, with depression next and ADHD indications probably further down the road.
EU Approval for Nerve Stimulator in Depression, Epilepsy
Emma Hitt, PhD
Sep 07, 2012
An external trigeminal nerve stimulation (eTNS) system (Monarch, NeuroSigma, Inc) has received European Union (EU) CE Certification for the adjunctive treatment of epilepsy and major depressive disorder for adults and children aged 9 years and older.
The device has been evaluated in clinical trials conducted at the University of California, Los Angeles (UCLA) and the University of Southern California. It consists of an external pulse generator and disposable electric patches placed on the forehead that are replaced daily and are worn primarily during sleep.